DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.023
EU - Europa 6.260
AS - Asia 3.369
SA - Sud America 490
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 7
Totale 21.239
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.705
PL - Polonia 1.704
CN - Cina 1.588
RU - Federazione Russa 1.322
IT - Italia 1.045
SG - Singapore 861
DE - Germania 553
BR - Brasile 426
GB - Regno Unito 354
UA - Ucraina 334
HK - Hong Kong 323
CA - Canada 282
SE - Svezia 255
FR - Francia 233
FI - Finlandia 168
KR - Corea 150
TR - Turchia 122
VN - Vietnam 109
IE - Irlanda 86
IN - India 59
BE - Belgio 39
JP - Giappone 38
NL - Olanda 34
EU - Europa 27
AR - Argentina 24
BD - Bangladesh 23
MX - Messico 23
ZA - Sudafrica 23
AT - Austria 21
ES - Italia 21
CZ - Repubblica Ceca 15
EC - Ecuador 12
AE - Emirati Arabi Uniti 11
RO - Romania 11
LT - Lituania 9
TW - Taiwan 9
CH - Svizzera 8
CO - Colombia 8
IR - Iran 8
RS - Serbia 8
TN - Tunisia 8
DK - Danimarca 7
PE - Perù 7
PK - Pakistan 7
UZ - Uzbekistan 7
ID - Indonesia 6
KE - Kenya 6
LB - Libano 6
PY - Paraguay 6
AM - Armenia 5
AU - Australia 5
EG - Egitto 5
IL - Israele 5
IQ - Iraq 5
MA - Marocco 5
SA - Arabia Saudita 5
VE - Venezuela 5
AL - Albania 4
AZ - Azerbaigian 4
BG - Bulgaria 4
DZ - Algeria 4
HR - Croazia 4
GR - Grecia 3
HU - Ungheria 3
JO - Giordania 3
LV - Lettonia 3
NO - Norvegia 3
PH - Filippine 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
ET - Etiopia 2
KH - Cambogia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
CM - Camerun 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
HN - Honduras 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ME - Montenegro 1
MQ - Martinica 1
MU - Mauritius 1
MW - Malawi 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
Totale 21.230
Salva come PNG Salva come JPEG
Città #
Warsaw 1.480
Fairfield 1.295
Woodbridge 971
Ashburn 814
Jacksonville 793
Houston 618
Chandler 567
Seattle 537
Wilmington 514
Ann Arbor 483
Cambridge 449
Singapore 356
Boardman 351
Dallas 349
Hong Kong 309
Beijing 267
Camerino 257
Nanjing 244
Kraków 213
Toronto 198
Los Angeles 156
The Dalles 131
Seoul 127
San Mateo 117
Tongling 116
Dearborn 111
Lawrence 111
Princeton 111
Columbus 107
London 101
New York 101
Istanbul 99
Moscow 90
Ogden 89
Dublin 84
Düsseldorf 81
San Diego 73
Nanchang 71
Buffalo 69
Shanghai 67
Helsinki 65
Chicago 64
Milan 60
Lachine 57
São Paulo 53
Guangzhou 52
Council Bluffs 51
Munich 50
Dong Ket 49
Kunming 46
Tianjin 45
Shenyang 41
Brussels 39
Jiaxing 37
Hebei 36
Centro 34
Rome 31
Tokyo 29
Ho Chi Minh City 28
Santa Clara 27
Frankfurt am Main 24
Hangzhou 24
Philadelphia 24
San Francisco 24
Atlanta 23
Changsha 23
Jinan 23
Wuhan 23
Falls Church 22
Redwood City 22
Hefei 20
Ningbo 20
Norwalk 20
Redondo Beach 20
Scafati 20
Phoenix 19
Denver 18
Jinhua 16
Poplar 16
Turku 16
Verona 16
Zhengzhou 16
Bologna 15
Manchester 15
Nuremberg 15
Stockholm 15
Venezia 15
Brooklyn 14
Chennai 14
Montreal 13
Rio de Janeiro 13
Salt Lake City 13
Tampa 13
Ancona 12
Boston 12
Johannesburg 12
Nürnberg 12
Orem 12
Taizhou 12
Washington 12
Totale 14.659
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 607
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 397
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 379
Overview on Radiolabel-Free in Vitro Assays for GPCRs 373
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 345
Pharmacological characterization of the GPR17 receptor dual profile 345
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 335
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 334
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 320
The G Protein-Coupled Receptor GPR17: Overview and Update 319
Emerging Roles of Purinergic Signaling in Diabetes 316
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 270
GPR17 receptor modulators and their therapeutic implications: review of recent patents 268
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 267
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 264
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 260
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 258
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 250
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 244
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 240
P2X7 Receptor as a Therapeutic Target 234
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 233
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 224
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 224
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 218
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 218
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 211
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 208
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 208
New sensible method to quantize the intestinal absorption of receptor ligands 205
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 205
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 203
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 201
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 201
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 198
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 198
Antiviral properties of deazaadenine nucleoside derivatives 194
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 194
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 193
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 193
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 193
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 192
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 192
Interaction model for anthracycline activity against DNA topoisomerase II 192
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 192
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 190
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 189
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 187
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 186
Adenosine receptor modeling: what does the A2A crystal structure tell us? 185
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 185
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 184
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 183
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 183
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 183
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 179
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 176
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 175
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 174
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 173
The P2X7 Receptor in Infection and Inflammation 173
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 173
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 171
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 170
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 167
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 166
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 164
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 164
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 160
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 158
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 154
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 154
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 151
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 151
I protocolli operativi nella violenza di genere 151
Development of novel pyridazinone-based adenosine receptor ligands 148
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 148
Rational design of new competitive inhibitors of human CK2 activity 141
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 139
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 138
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 137
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 136
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 135
null 134
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 131
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 130
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 129
Substituted adenine derivatives as novel P2X3 receptor ligands 127
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 124
New purine derivatives as P2X3 receptor antagonists 124
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 124
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 124
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 122
Letters in Drug Design & Discovery 122
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 116
Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies 114
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 113
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 112
Toward the rational design of Protein Kinase CK2 inhibitors 112
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 112
Totale 19.866
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.206
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.206
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.575 0 0 0 0 213 450 666 100 299 222 369 256
2021/20221.488 184 371 33 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/20241.247 161 64 80 49 57 114 65 92 138 44 45 338
2024/20254.107 180 74 330 195 135 258 476 1.025 340 283 277 534
2025/20262.478 367 349 702 813 247 0 0 0 0 0 0 0
Totale 21.651